Abstract OBJECTIVE: To evaluate the therapeutic efficacy of 3-year subcutaneous immunotherapy (SCIT) in asthmatic children allergic to mite. METHODS: Ninety asthmatic children allergic to house dust mite (with or without allergic rhinitis) and aged 5-14 years were randomized into SCIT treatment group (n=45) and control group (n=45). The SCIT treatment group received SCIT combined with standardized treatment for asthma, while the control group received the standardized treatment alone. The therapeutic effects were assessed based on the daytime and nighttime symptom scores, mean daily doses of inhaled corticosteroids (ICS), skin prick test results, peak expiratory flows and total serum IgE at baseline and in the 3-year treatment. RESULTS: In both groups, the daytime and nighttime symptom scores in the first, second, and third years of treatment were significantly lower than the baseline values (P<0.01), and the scores decreased year by year during the 3-year treatment (P<0.01). Also, the mean daily doses of ICS in the first, second, and third years of treatment were significantly lower than the baseline values (P<0.01), and the doses decreased year by year during the 3-year treatment (P<0.01). The mean daily dose was significantly lower in the SCIT treatment group than in the control group in the second and third years of treatment (P<0.05). After 3-year treatment, the SCIT treatment group had a significantly higher proportion of children who discontinued use of ICS due to remission of symptoms compared with the control group (29% vs 20%, P<0.05). At the end of the 3-year treatment, the total serum IgE was significantly lower than the baseline value in the SCIT treatment group (P<0.01), and it was significantly lower in the SCIT treatment group than in the control group (P<0.05). CONCLUSIONS: Three-year SCIT is effective in asthmatic children allergic to house dust mite and allows reduction in the dosage of ICS.
LI Ling,HUI Yu,QIAN Jun et al. Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite[J]. CJCP, 2013, 15(5): 368-371.
LI Ling,HUI Yu,QIAN Jun et al. Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite[J]. CJCP, 2013, 15(5): 368-371.
［1］Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial［J］. Clin Exp Allergy, 2010, 40(6): 922-932.
［2］Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma［J］. Allergy, 2011, 66(2):178-185.
［4］Basomba A, Tabar AI, de Rojas DH, Garcia BE, Alamar R, Olaguibel JM, et al. Allergen vaccination with a liposomeencapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients［J］. J Allergy Clin Immunol, 2002, 109(6): 943-948.
［5］Klimek L, Mewes T, Wolf H, Hansen I, Schnitker J, Mann WJ. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity［J］. Otolaryngol Head Neck Surg, 2005, 133(4): 538-543.
［7］Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma［J］. J Allergy Clin Immunol, 2000, 105(2): 559-575.
［8］Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?［J］. Ann Allergy Asthma Immunol, 2007, 98(5): 416-426.
